Search research articles
Contact Us
Filters
Showing results (91-100 of 113) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Cancer
|
November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Jayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.
The Lancet. Oncology
|
January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
Tomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2021
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association
|
November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial
Susan Halabi, Qian Yang, Andrea Carmack, et al.
Oncology
|
August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program
Ronald M Bukowski, Walter M Stadler, David F McDermott, et al.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 113) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.
Cancer
|
November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Jayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.
The Lancet. Oncology
|
January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
Tomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2021
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma
Andrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association
|
November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial
Susan Halabi, Qian Yang, Andrea Carmack, et al.
Oncology
|
August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program
Ronald M Bukowski, Walter M Stadler, David F McDermott, et al.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Page
of 12